Veradermics, Inc
No SEC Form 4 filings for $MANE in the last 30 days.
See all $MANE insider activity →Veradermics (NYSE: MANE), a biotech company, saw its shares rise 268% post-IPO. Its lead therapy, VDPHL01, showed positive phase 3 trial results, with 78.8% to 85% of patients reporting hair coverage improvements. The drug targets a $30B market for pattern hair loss. The company has $820M in cash and analysts' average price target is $170.
Disc Medicine (IRON) surged 38.86% to $78.93, leading healthcare gains. Cleveland-Cliffs (CLF) rose 16.34% to $14.10 in materials. Almonty Industries (ALM) fell 10.17% to $8.83, among notable decliners.
Veradermics, Inc (MANE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with h
Over the past 7 days, AlphAI's AI scored 1 news story mentioning MANE (Veradermics, Inc). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent MANE coverage spans financial news, market movers and technology.
Positive pivotal data is likely to lift the stock as investors price in potential FDA approval.
Price increase lacks disclosed news.
Positive trial data suggests VDPHL01 could become the first FDA‑approved oral hair loss treatment, likely driving near‑term stock upside.
Target raise reflects positive outlook.
Needham maintained a Buy rating on Veradermics with a $172 price target, suggesting a 58.1% upside from the Oct 16 close. The firm cited positive clinical trial results for VDPHL01, showing 68.7% efficacy in female subjects, and regulatory/commercial de-risking due to Phase 3 trial success.
AlphAI scores every news story that mentions MANE with an AI model for sentiment and relevance, and aggregates insider trades from Veradermics, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Veradermics (NYSE: MANE), a biotech company, saw its shares rise 268% post-IPO. Its lead therapy, VDPHL01, showed positive phase 3 trial results, with 78.8% to 85% of patients reporting hair coverage improvements. The drug targets a $30B market for pattern hair loss. The company has $820M in cash and analysts' average price target is $170.
2 min readDisc Medicine (IRON) surged 38.86% to $78.93, leading healthcare gains. Cleveland-Cliffs (CLF) rose 16.34% to $14.10 in materials. Almonty Industries (ALM) fell 10.17% to $8.83, among notable decliners.
2 min readVeradermics, Inc (MANE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and secondary endpoints with h
2 min readAnalysts updated price targets for several companies. Bernstein raised Microsoft's target to $662, maintaining an Outperform rating. Morgan Stanley increased Global-E Online's target to $50 and upgraded it to Overweight. Other notable changes include Truist Financial, Annexon, Ameriprise Financial, Lyft, A O Smith, Hudson Pacific Properties, Boyd Gaming, and Veradermics.
2 min readNeedham maintained a Buy rating on Veradermics with a $172 price target, suggesting a 58.1% upside from the Oct 16 close. The firm cited positive clinical trial results for VDPHL01, showing 68.7% efficacy in female subjects, and regulatory/commercial de-risking due to Phase 3 trial success.
1 min readVeradermics (MANE) will host a call on Oct. 19, 2026, to review topline results from its Phase 3 ‘304’ trial of VDPHL01 for hair loss in over 500 males. The trial's success depends on efficacy and safety data, with regulatory clarity as a follow-up step, according to the company.
1 min readPacira BioSciences (PCRX) surged 44% to $36.46 after Vitaris agreed to acquire it for $1.65B. Veradermics (MANE) rose 14% to $136.72, while HealthStream (HSTM) gained 2% to $32.42. Concentra (CON) and Haemonetics (HAE) also hit 52-week highs on strong financials.
2 min readOn 8 October 2026, Haemonetics (HAE) rose 17.46% to $119.47, while Applied Optoelectronics (AAOI) fell 13.58% to $105.90. Other notable movers included Veradermics (MANE), Securitize (SECZ), The Vita Coco Company (COCO), Erasca (ERAS), MaxLinear (MXL), argenx (ARGX), EquipmentShare.com (EQPT), and Hut 8 (HUT).
2 min readVeradermics Incorporated (NYSE: MANE) shares rose 15.68% on promising dermatology clinical trial results. The company reported a quarterly net loss of $23.5M but holds $319.3M in cash and minimal debt. MANE's stock has surged from $101.70 to $136.72 in recent weeks, driven by strong momentum and trader interest.
3 min readVeradermics (MANE) and Absci (ABSI) shares have surged as investors bet on the hair-loss drug market. Veradermics reported positive trial results for an oral minoxidil tablet, while Absci is developing an AI-designed injectable treatment. Both companies face competition and clinical risks, with no new FDA-approved hair-loss drug since the 1990s.
2 min read
